User:Kerry Frattarola/Sandbox 1: Difference between revisions

Revision as of 06:45, 16 November 2016

Indinavir acts with the Asp25, Thr26 and Gly27 subunits in the HIV-1 protease enzyme.^[1]

Structure of HIV-1 protease mutant bound to indinavir, (2b7z), resolution 2.20Å

Drag the structure with the mouse to rotate

↑ Mager PP. The active site of HIV-1 protease. Med Res Rev. 2001 Jul;21(4):348-53. PMID:11410934

@@ Line 1: / Line 1: @@
 ==Human Immunodeficiency Virus protease inhibitor==
+<applet   load="" size="350" color="" frame="true"  spin="on" Scene ="Indinavir/Indinavir/1" align="right" caption="Indinavir, better known as Crixivan, ([[1hsg]])"/>
 <StructureSection load='2b7z' size='340' side='right' caption='Structure of HIV-1 protease mutant bound to indinavir, ([[2b7z]]), [[Resolution|resolution]] 2.20&Aring;' scene=''>
 <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''>
 ==Structure==
-Indinavir is an antiviral compound that acts as a protease inhibiter. Figure 2 below depicts Indinavir’s structure. The drug has a molecular weight of 711.875 g/mol and is very soluble in water and ethanol. Indinavir works by specifically binding to the HIV-1 protease active site by mimicking a target substrate protein and essentially becoming “stuck” in the enzyme active site, disabling the enzyme. The Arginine in the protease interacts with Indinavir’s pyridine to hold it in place. The hydroxyl groups off the cyclopentanes, ketone and amide interact with the Asp25 of HIV-1 protease to perform catabolism (1).
 == Function ==